Patents for A61P 35 - Antineoplastic agents (221,099)
03/2009
03/18/2009CN100469789C Variants of allergenic proteins of the Group2 of dermatophagoides
03/18/2009CN100469784C Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
03/18/2009CN100469783C Oligose ,sulfating product and oligose cluster and its uses
03/18/2009CN100469778C Novel fused imidazole derivative
03/18/2009CN100469773C Preparation method and usage for nitrogen-containing flavone derivatives
03/18/2009CN100469767C Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors
03/18/2009CN100469371C Manufacturing technique for gingko leaf extracts
03/18/2009CN100469363C Therapeutic combinations of fatty acids
03/18/2009CN100469361C Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
03/18/2009CN100469253C Method for preparing tumor mutation-resisting yoghourt with micron ash tree pollen, pine pollen, bee pollen and ganoderma lucidum spore powder
03/17/2009US7504507 carboxamide linked compounds based on benzo[b][1,6]naphthyridin-1 (2H)-one, which differ from previous acridine based compounds by the incorporation of a lactam or thiolactam function in one of the outer rings
03/17/2009US7504482 Recombinant soluble Fc receptors
03/17/2009US7504479 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
03/17/2009US7504421 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
03/17/2009US7504416 4-substituted quinolines as antitumor agents
03/17/2009US7504414 Useful as adjuvants to chemotherapy or radiation therapy to treat cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2); 2-[4-(3,4-dichloro-phenoxy)-phenyl]-1H-imidazo[4,5-b]pyridine-5-carboxylic acid amide
03/17/2009US7504412 Melanin concentrating hormone receptor antagonists; such as n-(2-cyclopropyl-3-methylimidazo[1,2-a]-pyridin-6-yl)-4-(2-pyridyl)benzamide; central nervous system, cardiovascular and metabolic disorders; synthesis
03/17/2009US7504410 such as N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide; Chks (checkpoint kinases), Akts (protein kinases B) and Pdks (phosphoinositide-dependent kinases) inhibitors; antiproliferative agents
03/17/2009US7504408 Quinzoline derivatives for use in the treatment of cancer
03/17/2009US7504405 Mitotic kinesin inhibitors
03/17/2009US7504398 potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation
03/17/2009US7504247 2-O sulfatase compositions and methods of degradation therewith
03/17/2009US7504232 Identifying immunomodulators for diagnosis and treatment of inflammatory, granulomatous, fibrosis, multiple sclerosis, bacterial or viral diseases
03/17/2009US7504115 Shark cartilage extracts and use thereof for immunomodulation
03/17/2009US7504104 Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens
03/17/2009US7504102 Therapeutic mixture comprising immunoglobulin specific to vitronectin receptor for use in diagnosis, prevention and treatment of restenosis
03/17/2009US7504100 Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow
03/17/2009CA2639658A1 Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs
03/17/2009CA2412594C Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
03/17/2009CA2412161C Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
03/17/2009CA2360668C The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
03/17/2009CA2338638C Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
03/17/2009CA2330025C Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
03/17/2009CA2328234C Compounds that inhibit the binding of integrins to their receptors
03/12/2009WO2009033140A1 Microrna signatures in human ovarian cancer
03/12/2009WO2009033084A1 Pyrazolo-pyridines as tyrosine kinase inhibitors
03/12/2009WO2009032930A2 Compositions comprising human integrin-linked kinase-sirna and methods of use thereof
03/12/2009WO2009032703A1 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
03/12/2009WO2009032668A2 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
03/12/2009WO2009032667A1 Thiazole and oxazole kinase inhibitors
03/12/2009WO2009032364A1 Activation of nuclear factor-kappa b
03/12/2009WO2009031999A1 Fr901464 and analogs with antitumor activity and method for their preparation
03/12/2009WO2009031876A1 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer
03/12/2009WO2009031709A1 Coumarin compound and use thereof
03/12/2009WO2009031708A1 Coumarin compound and use thereof
03/12/2009WO2009031706A1 Coumarin compound and use thereof
03/12/2009WO2009031705A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING ACCUMULATION OF AMYLOID-β PROTEIN
03/12/2009WO2009031671A1 Method for promoting the expression of p53, and p53 expression promoter for use in the method
03/12/2009WO2009031230A1 Anti-cd20 monoclonal antibodies
03/12/2009WO2009031195A1 Composition containing flavanone compound monomer
03/12/2009WO2009031151A2 Antibodies and methods for diagnosing and treating cancer
03/12/2009WO2009030998A1 Pyrimidine compounds as toll-like receptor (tlr) agonists
03/12/2009WO2009030996A1 Triazole compounds as toll-like receptor (tlr) agonists
03/12/2009WO2009030952A2 Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
03/12/2009WO2009030890A1 Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
03/12/2009WO2009030871A1 Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
03/12/2009WO2009030734A1 Intraoperative trifunctional antibody administration for prophylaxis of intraperitoneal tumor cell dissemination
03/12/2009WO2009030368A1 Combination therapy with type i and type ii anti-cd20 antibodies
03/12/2009WO2009030333A1 Thiadiazinone derivatives
03/12/2009WO2009030316A1 1,3-dihydroisoindole derivatives
03/12/2009WO2009030103A1 The uses of salmonella typhi or salmonella paratyphi for preparation of medicaments for combating tumors
03/12/2009WO2009030094A1 Function and use of new lysosome-associated apoptosis-inducing protein containing ph and fyve domains (lapf)
03/12/2009WO2009030092A1 Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof
03/12/2009WO2009030088A1 Function and use of a new human calcium/calmodulin-dependent protein kinase ii inhibitor
03/12/2009WO2009030086A1 Functions and uses of human bone marrow stromal cell-derived growth inhibitor
03/12/2009WO2009030084A1 NEW FUNCTIONS AND USES OF HUMAN ONCOGENE-LIKE SMALL G PROTEIN RabJ
03/12/2009WO2009030073A1 A dTDP-β-D-FUCOFURANOSE, ITS PREPARATION METHOD AND USE
03/12/2009WO2009030066A1 Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof
03/12/2009WO2009030065A1 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
03/12/2009WO2009029998A1 Retrometabolic compounds
03/12/2009WO2009011617A3 ANNELATED AZAHETEROCYCLES COMPRISING PYRIMIDINE FRAGMENT, METHOD FOR THE PRODUCTION THEREOF AND (PI3Ks) KINASE INHIBITORS
03/12/2009WO2009010139A3 Quinazolinamide derivatives
03/12/2009WO2008149244A3 Compositions and methods comprising analogues of radicicol a
03/12/2009WO2008146167A3 Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
03/12/2009WO2008136850A3 Cobalamin conjugates useful as imaging and therapeutic agents
03/12/2009WO2008136018A3 4beta-amin0 podophyllotoxin congeners as potential anticancer agents and a process for the preparation thereof
03/12/2009WO2008113557A3 Anti-infective agents
03/12/2009WO2008110624A9 Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors
03/12/2009WO2008109498A3 Nucleic acid compounds for inhibiting hdac gene expression and uses thereof
03/12/2009WO2008079849A3 Antibodies to insulin-like growth factor receptor
03/12/2009WO2008059052A9 Improved methods of using phosphoantigen for the treatment of cancer
03/12/2009WO2008040362A3 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
03/12/2009WO2008021389A8 Using pi3k and mek modulators in treatments of cancer
03/12/2009WO2008014219A8 Thiozolidinedione derivatives as p13 kinase inhibitors
03/12/2009WO2008013807A9 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
03/12/2009WO2006122806A3 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
03/12/2009US20090069564 Methods and Compositions for Selectin Inhibition
03/12/2009US20090069441 Motuporamine Mimic Agents
03/12/2009US20090069434 Cystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/12/2009US20090069432 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
03/12/2009US20090069424 TGF-alpha expression inhibitors
03/12/2009US20090069420 Small molecule inhibitors of STAT3 with anti-tumor activity
03/12/2009US20090069417 Carotenoid oxidation products as chemopreventive and chemotherapeutic agents
03/12/2009US20090069410 Deuterium-enriched paclitaxel
03/12/2009US20090069409 Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
03/12/2009US20090069402 Deuterium-enriched atrasentan
03/12/2009US20090069396 Polyene Oxazoles and Processes for Their Preparation
03/12/2009US20090069394 Cancer treatment with epothilones
03/12/2009US20090069393 Parenteral formulation for epothilone analogs
03/12/2009US20090069391 such as N-hydroxy-6-{1-[(4-methoxybenzyl)amino]-2-[(4-methoxyphenyl)amino]-2-oxoethyl}-1-benzothiophene-2-carboxamide, used to treat cancer, tumors, neurodegenerative, autoimmune, allergic and inflammatory diseases, and as histone deacetylase inhibitors